Neon data highlights epitope spread as key metric for neoantigen vaccines

Interim results from Neon's Phase Ib trial of NEO-PV-01 plus Opdivo nivolumab suggest proof of epitope spread will be a telling readout for neoantigen cancer vaccines. The data also point to tumor microenvironment-based predictors of therapeutic response.

Clinical data trickling in from early

Read the full 422 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE